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ABSTRACT 
 
The pharmacological treatment of major depressive disorder 
(MDD) fails to respond in 30% to 50% of the cases, 
triggering researchers to dig deeper into the neurobiological 
underpinnings of depression. This has put the immune 
system (IS) in the spotlight and induced the formulation of 
the “cytokine hypothesis of depression” according to which 
—immune response act as neuromodulator that mediate the 
behavioural and neurobiological features of depression—. 
Objective: In our paper we aim to deepen into the 
relationship between chronic inflammation of the IS and 
depression, in order to understand why some people fail to 
respond to the main pharmacological treatment. Method: 
Application of a systematical research in relevant databases 
and following the main authors in this particular branch of 
psychoneuroimmunology. Results: Monoamine treatment 
and IS interact and modify each other, suggesting that the 
lack of clinical therapeutic benefit of antidepressants (AD) is, 
somehow, associated with overall activation of the 
inflammatory system. Discussion: Since the current literature 
demonstrates an association between antidepressant action 
and cytokine function in MDD, we suggest a new treatment 
approach merging the actual pharmacological treatment with 
a behavioural pre-anti-inflammatory treatment in the 
mindfulness’ line that is demonstrated to be able to reduce 
the chronic inflammation of the IS. 
 
1. Introduction 
Major depressive disorder (MDD) is 
predicted to be the second leading cause 
of disability by 2020 (Baune, 
Dannlowski, Domschke, Janssen, 
Jordan, Ohrmann, et al. 2010; Powell, 
Smith, Hackinger, Schalkwyk, Uher, 
McGuffi, et al. 2012). Lifetime 
prevalence rates of major depression are 
estimated to be 20% in women and 
about 10% in men (Steffens et al. 2000, 
cfr. Irwin 2002). Depression predicts 
mortality whether it is considered for 
many authors as a disorder or treated as 
a continuous risk factor (cfr. Irwin 
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2002). The factors that contribute to the 
more chronic nature of depression are 
not entirely known although the 
presence of chronic disease, exposure to 
stressful life events and personal losses, 
diminished social supports, and declines 
in self-concepts of efficacy and mastery 
are suggested (Blazer, 1989, cfr. Irwin 
2002). Although monoamine-pathway 
targeted AD are the main treatment 
choice, two-thirds of patients fail to 
respond to the first AD prescribed and 
the remaining third fails to respond to 
multiple AD treatments (Miller, 
Maletic, and Raison, 2009; Powell, et 
al. 2012).  
The insufficiency of the monoamine 
hypothesis to explain several aspects of 
mood regulation has resulted in an 
expanded search for the neurobiological 
underpinnings of depression (Anders, 
Tanaka and Kinney, 2013). Numerous 
researches have been interested in the 
role of the IS the in etiology, course and 
treatment of MDD (Maier and Watkins, 
1998; Irwin, 2002; Irwin and Miller, 
2007; Leonard and Myint, 2009; Miller, 
et al, 2009; Janssen, Caniato, Verster 
and Baune, 2010).  
Maes et al. (1993, cfr. Maes, Berk, 
Goehler, Song, Anderson, et al. 2012) 
hypothesized about the bidirectional 
communication and the relationship that 
both immune and central nervous 
system (CNS) hold. It is now generally 
accepted that immune dysregulation 
plays an important role in the 
pathogenesis of major depression (Gold 
and Irwin 2006, cfr. Janssen et al. 
2010). The role of the immune-activated 
inflammatory cytokines has been 
identified as a key area of focus in 
understanding the neurobiological 
pathways that trigger depressive states 
(Janssen et al. 2010; Anders, et al. 
2013). The term cytokine encompasses 
a large and diverse family of signalling 
molecules that primarily gave immune 
modulating activity and that are 
produced widely throughout the body 
by cells of diverse embryological origin. 
Cytokines are primarily protein peptides 
or glycoproteins, used extensively in 
immune modulation, secreted by a wide 
variety of cells in the IS, which play a 
role in the pathogenesis of numerous 
disorders including infection, 
autoimmune disease, stroke and even 
depression. Traditionally they can be 
classed as lymphokines, interleukins 
(IL), and chemokines, depending on 
their presumed function, target, or cells 
of origin (Janssen et al. 2010). 
Increased levels of pro-inflammatory 
cytokines (PICs) have been repeatedly 
observed in depressed individuals 
prompting the formulation of the 
“Cytokine hypothesis of depression” 
(Anders et al. 2013). 
 
The cytokines-depression hypothesis 
postulates that AD may prevent the 
onset of sickness behaviour by 
modulating PICs (Janssen et al. 2010). 
While there are good evidences which 
suggest that inflammation can 
contribute to the development of 
depression it is less evident that 
blocking inflammation will lead to a 
reduction of depressive symptoms or be 
efficacious in treatment-resistant 
depression (Jones and Thomsen, 2013). 
Existing data indicates that 
inflammatory biomarkers may identify 
depressed patients who are less likely to 
respond to conventional AD treatment 
(Miller et al. 2009) which may be also 
relevant to the potential clinical 
applications of the association between 
inflammation and depression. 
 
One of the firsts in hypothesize about 
the shared pathways between the IS and 
the CNS were Maier and Watkins in 
1998, in their article “Cytokines for 
Psychologists: Implications of 
Bidirectional Immune-to-Brain 
Communication for Understanding 
Behaviour, Mood and Cognition” in 
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which they described how PICs are 
known to mediate in a behavioural 
complex induced by infection and 
immune trauma called “Sickness 
Behaviour” (Maier and Watkins, 1998; 
Anders et al. 2013). Sickness behaviour 
is characterized by somatic, cognitive, 
and behavioural changes, such as fever, 
weakness, malaise, and impaired 
concentration (Hart 1988, cfr. Anders, 
et al. 2013), it has an evident similarity 
with clinical depression. The first 
inkling that there are phenomenological 
similarities between those two 
conditions may share common 
pathways, that is, activation of the 
inflammatory responses system was 
published in 1993 (cfr. Myers, 2008; 
Maes et al. 2012). 
Therefore, in this paper we aim to 
clarify how some specific molecules of 
the IS (cytokines) interact with AD, and 
how this interaction affects the efficacy 
of the pharmacological treatment in 
MDD. We will also attempt to analyse 
an alternative treatment for depression 
which is based on the belief that 
improving the inflammatory state of the 
IS will, somehow, alleviate depression 
symptoms. We hope our research 
pathway will guide future research 
efforts in depression and AD treatment 
response.  
2. Method 
We have built a systematic review of 
the pubmed, psychinfo, pubpsych and 
the UAB library’s catalog “el trobador 
+” databases with articles published 
between 2004 and 2015. We have also 
searched in the first reviewed articles’ 
bibliography in order to select those we 
found more interesting. With an 
exception for articles that are the bases 
for knowledge in 
psychoneuroimmunology and its 
relation with depression, such as the 
Maier and Watkins’ article which was 
written in 1998,  and the review made 
by Irwin in 2001. The searches applied 
in the databases were 
Psychoneuroimmunology AND 
depression AND treatment failure, and 
also, Psychoneuroimmunology AND 
depression AND cytokines AND 
antidepressants. We have finally used 
45 reviews or meta-analysis, all of them 
in English.  
 
3. Linkage between the immune 
system and depression 
 
3.1. Depression 
Depressive syndromes and major 
depression are exceedingly common, 
and they are a chronic and recurrent 
disorder with residual disability. Nearly 
one in four women and one in six men 
experience depression during their 
lifetime (Kessler et al. 2010, cfr. 
Slavich and Irwin, 2014). In fact, 
depression has been estimated to be the 
fourth leading cause of overall disease 
burden and the leading cause of nonfatal 
disease burden worldwide (Üstün et al. 
2004, cfr. Slavich and Irwin, 2014), and 
in primary care outpatients, point 
prevalence rates ranges from 9% to 20% 
for all depressive disorders (Barry et al. 
1998, cfr. Irwin, 2002). The factors that 
contribute to the more chronic nature of 
depression are not fully known, 
although the presence of chronic 
disease, exposure to stressful life events 
and personal losses, diminished social 
supports, and declines in self-concepts 
of efficacy and mastery are suggested 
(Blazer, 1989, cfr. Irwin, 2002). 
Less is known about the effects of 
major depression on the outcomes of 
other diseases and whether depression 
alters the onset and progression of 
chronic medical disorders such as 
infectious disease and/or inflammatory 
disorders (Irwin, 2002). There is now 
substantial evidence that psychological 
stress can trigger significant increases in 
inflammatory activity (i.e. in the 
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absence of physical injury; Glaser and 
Kiecolt-Glaser, 2005, cfr. Slavich and 
Irwin, 2014). Increases in inflammation 
can in turn elicit profound changes in 
behaviour, which include the initiation 
of depressive symptoms such as sad 
mood, anhedonia, fatigue, psychomotor 
retardation, social-behavioural 
withdrawal (Slavich and Irwin, 2014). 
These somatic, cognitive and 
behavioural changes caused by PICs 
have been defined by many authors as 
sickness behaviour (we will delve into it 
later on this paper) and it represents an 
organized strategy for fighting infection 
by conserving metabolic resources and 
helping individual avoid further 
stressors (Anders et al. 2013). If it is 
substantiated that biobehavioural factors 
impact immune related diseases, then it 
is equally important to know whether 
interventions that influence 
psychological adaptation can have 
attendant effects on immunological and 
health status outcomes (Irwin, 2002). 
The mechanisms that count for this 
relationship between depression and 
progression of immune-related 
disorders were treated with special 
attention in Irwin’s paper (2002). There 
are few fundamental pathways by which 
cytokines may contribute to depression, 
they have been shown to access into the 
brain and interact with virtually every 
pathophysiologic domain relevant to 
depression, including neurotransmitter 
metabolism, neuroendocrine function, 
and neural plasticity (Dantzer, 
O’Connor, Freund, Johnson and Kelly, 
2008; Raison et al,. 2006, cfr. Miller et 
al. 2009). 
It remains unclear whether activation of 
inflammatory pathways in the CNS 
during depression originates primarily 
in the periphery and/or whether stress or 
other yet to be identified processes 
induce inflammatory directly within the 
brain (Miller et al. 2009). 
 
3.2. Understanding depression 
For more than half a century, efforts to 
understand the neurobiological 
underpinnings of depression have been 
dominated by the view of many authors 
that depression is caused by a 
deficiency in synaptic concentrations of 
monoaminergic neurotransmitters, 
including serotonin and norepinephrine 
(Anders et al. 2013). This idea has been 
called the monoamine hypothesis and 
has become the basis for most of the 
treatments in the market. However, the 
efficacy of AD drugs based on the 
fundamental premise of the monoamine 
hypothesis has been limited, with 
estimates between 30% and 50% of 
individuals treated with AD medication 
not showing adequate response 
(Schatzberg, 2000, cfr. Anders et al. 
2013). 
The credibility of the monoamine 
theory and the therapeutic efficacy of 
these compounds in the treatment of 
depression have been extensively 
criticized, and in many instances the 
evidence used to support these 
criticisms is found to be weak (Walker, 
2013). Research on the IS and its role in 
the etiology of depression has emerged 
as an especially promising area for 
study, in particular, the role of immune-
activated inflammatory cytokines, a key 
area of focus in understanding the 
neurobiological pathways that trigger 
depressive states by way of direct and 
indirect effects on hypothalamic-
pituitary-adrenal (HPA) axis, and by 
altering monoamine neurotransmitters 
in multiple regions of the brain (Anders 
et al. 2013).  
3.3. Sickness Behaviour 
When infection or injury occurs, PICs 
are responsible of orchestrating the 
early immune response, including 
sickness behaviour, characterized by 
somatic, cognitive, and behavioural 
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changes, such as fever, weakness, 
malaise, listlessness, hyperalgesia, and 
impaired concentration, represents an 
organized strategy for fighting infection 
by conserving metabolic resources and 
helping an individual avoid further 
stressors (Anders et al. 2013).  
According to Dantzer (2001, 2009) 
sickness behaviour is an expression of a 
biologically-mediated motivational state 
triggered by the innate IS that resets an 
organism’s priorities to adaptively cope 
with the threat of bodily insult. The 
costs of shifting resources and priorities 
during this state are purportedly offset 
by the critical advantages offered for 
fighting infection (Dantzer 2001, 2009; 
Anders et al. 2013).  
Comparing both, clinical depression and 
sickness behaviour it is easy to find a 
clear similarity (Maes et al. 2012). For 
example, similar to sickness behaviour, 
symptoms of depression such as 
anhedonia, fatigue, hypersomnia, 
anorexia and psychomotor retardation 
(i.e. slowed speech, thinking, and body 
movements) all tend to reduce activity 
and encourage rest, thereby conserving 
energy. Although there are many 
similarities, there are also significant 
differences such as the length of course, 
the variety of symptoms or the mood. 
Therefore, we conclude that this may be 
evidence that PICs are involved in 
depression, since physical 
symptomatology is equivalent to 
sickness behaviour (Anders et al. 2013). 
3.4. Role of inflammation in 
depression. A particular focus 
on pro-inflammatory cytokines  
Numerous associations have been 
observed between depression and IS in 
recent years (Musselman et al. 1998, 
cfr. Irwin 2002). Psychological and 
physical stressors increase the release of 
PICs and alter expression of adhesion 
molecules. For example, Appels et al. 
(2000) have found that angioplasty 
patients with feelings of exhaustion and 
depression have higher levels of IL-1 
and TNF (cfr. Irwin, 2002). 
Increased levels of PICs have been 
repeatedly observed by lots of authors 
in depressed individuals, prompting 
formulation of the “macrophage theory 
of depression” (Smith, 1991, cfr. 
Anders et al. 2013), and its successive 
formulation as the ‘cytokine hypothesis 
of depression’ (Anders et al. 2013). 
According to the cytokine hypothesis, 
PICs produced by macrophages during 
the acute phase of an immune response 
act as neuromodulators that mediate the 
behavioural and neurobiological 
features of depression (Anders et al. 
2013). 
Cytokines are the key mediator of 
inflammation; therefore they can alter 
neurochemical and neuroendocrine 
processes that have wide-ranging effects 
on physiology and behaviour. This 
review focuses primarily on PICs IL-1, 
IL-6, and TNF-α, which together 
coordinate a variety of cell functions 
that stimulate and enhance 
inflammation. For example, they 
promote the differentiation of 
lymphocytes called cytotoxic T cells, 
which kill pathogens that are introduced 
into the body during physical wounding 
(cfr. Slavich and Irwing, 2014).  
Inflammatory cytokines also promote 
increased vascular permeability and 
cellular adhesion, which allows immune 
cells to leave the blood vessels (i.e. the 
“boulevards”) and migrate to tissues 
(i.e. the “battlefields”) where they can 
neutralize or eliminate pathogens 
(Dhabhar et al. cfr. Slavich and Irwin 
2014). Chemokines (a family of small 
cytokines) are activated by the PICs 
TNF-α, IL-6, and IL-1, and they 
continually survey the body to screen 
for pathogens in a process called 
immunosurveillance. Once a pathogen 
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or infection has been identified, 
chemokines can act as chemoattractants 
that recruit other immune cells to the 
site of inflammatory activity (Murphy, 
2011, cfr. Slavich and Irwin, 2014). 
3.5. Inflammation: Friend and Foe  
Down-regulating the response once a 
pathogen has been cleared is, according 
to Kushner (1982) and Medzhitov 
(2008) critical to resolve infection, 
repair tissue damage, and return the 
body to a state of homeostasis (cfr. 
Slavich and Irwin, 2014). An altered or 
prolonged response can actually cause 
more damage to a host than the 
pathogen itself (Barton, 2008, cfr. 
Slavich and Irwin, 2014). Indeed, it is 
now widely recognized that chronic 
inflammation plays a role in several 
major diseases including asthma, 
arthritis, diabetes, obesity, 
atherosclerosis, certain cancers, and 
Alzheimer’s disease (Couzin-Frankel, 
2010, cfr. Slavich and Irwin, 2014). 
And according to Segerstrom and 
Miller, (2004) and Steptoe et al. (2007), 
one factor that can alter the adaptive 
response of innate IS and prolong 
inflammation is stress.  
But how does the immune and nervous 
system communicate in order to 
orchestrate such a diverse pattern of 
changes? Quoting Maier and Watkins 
(1998):  
“The most obvious possibility is 
that cytokines travel to the brain 
in the bloodstream and cross the 
blood-brain barrier. This 
pathway is credible considering 
that there are specific receptors 
for IL-1, IL-6 and TNF in the 
brain and neurons. Also blocking 
IL-1 receptors in the brain can 
prevent some of the sickness 
responses to peripheral 
administration of cytokines and 
that the administration of IL-1 
directly to the brain produces 
many of the sickness responses 
(p. 88).”  
But as cytokines are large lipophobic 
molecules they are not likely to cross 
the blood-brain barrier and enter the 
brain. Numerous investigations 
proposed different specialized 
mechanisms such as active transport, 
weak brain-barrier areas, and receptor 
inside the blood vessels may allow 
cytokines access to the brain; however it 
does not seem to be sufficient to 
produce psychological changes (cfr. 
Maier and Watkins, 1998). According 
to Maier and Watkins (1998) there are 
alternative communication pathways 
between the brain and the IS. The CNS 
receives neural and humoral signals 
about the peripheral inflammatory 
response thought PIC-induced 
activation of afferent vagal signals, 
effects of TNF-α at the sensory nuclei 
of the solitary tract, and all three PICs 
entering the brain through the different 
mechanisms prior mentioned (Maes et 
al. 2012) affecting hypothalamus, and 
hippocampus. This is where the neural 
cascade begins which result in 
individual responses that are known as 
sickness (Maier and Watkins, 1998). 
The most pronounced changes are in 
norepinephrine and serotonin release 
and action (Linthorst et al. cfr. Maier 
and Watkins 1998). We will talk about 
the importance of these monoamine 
responses later on this paper.  
So far we have shown different 
hypothesis undergoing the etiology of 
MDD, such as the monoaminergic 
hypothesis or the cytokine-based 
hypothesis, but none of these can 
completely explain the variety of 
symptoms of this heterogeneous 
disorder. We have also observed how 
the IS talks to the brain through 
different pathways affecting the brain 
and causing behavioural changes. Next 
we will explain the exact pathways by 
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which cytokines are believed to 
orchestrate such a diverse pattern of 
changes. 
4. Synergic relationship between 
cytokines and CNS 
The efforts to understand the 
neurobiological underpinnings of 
depression have been dominated by the 
view that depression is caused by a 
deficiency in synaptic concentrations of 
monoaminergic neurotransmitters 
including serotonin and norepinephrine 
(Anders et al. 2013). This belief is 
known as “monoaminergic hypothesis 
of depression”. The majority of 
currently used AD drugs act on the 
monoamine serotonin neurotransmitter 
systems (Roman, Kreiner and Nalepa, 
2013), and the prescription of selective 
serotonin reuptake inhibitors (SSRIs) is 
a major component in the medical 
treatment of mood related 
psychopathology (Walker, 2013).  
The efficacy of these AD drugs based 
on the fundamental premise of the 
monoamine hypothesis has been 
limited, especially because it is 
estimated that between 30% and 50% of 
individual treated with AD medication 
do not show adequate response 
(Schatzberg, 2000 cfr. Anders et al. 
2013). It is now clear that this 
hypothesis by itself does not answer all 
the questions about the etiology of 
depression due to the lack of therapeutic 
efficacy of its treatment.  
Lots of hypothesis has been made since 
the SSRIs launching in 1972 but it is 
now obvious that cytokines play an 
important role in the etiology of mood-
related disorders. They can exert direct 
and indirect effects on brain function 
through their influence on 
neurotransmitter, neurogenesis and the 
HPA axis influencing neuroplastic 
changes relevant to depression (Bauer, 
Papadopoulos, Poon, Perks, Lightman, 
Checkley, and Shanks, 2003; Eyre and 
Baune, 2012; Mills, Scott, Wray, 
Cohen-Woods and Baune, 2013; Felger 
and Lotrich, 2013).  
The evidence for inflammatory changes 
in the brain in depression suggests that 
an increase in inflammation-induced 
apoptosis, together with a reduction in 
the synthesis of neurotrophic factors 
caused by a rise in brain 
glucocorticoids, may also play a role in 
the pathology of these disorders. If this 
is the case, it is expected that the more 
severe cases of depression —those who 
are resistant to AD treatment— present 
higher inflammatory disturbance 
(Carvalho, Torre, Papadopoulus, Poon, 
Juruena, Markopoulu, et al. 2012). 
In order to define treatment resistance 
we will use Sackeim’s (2001) 
definition: resistance to a given 
treatment is concluded if, despite 
continued adherence to the same 
medication and dosage that produced an 
initial response, a patient experienced 
relapse or recurrence of a depressive 
episode. There is also the Thase and 
Rush (1997) staging criteria, which 
recognises five stages of treatment-
resistance according to the number of 
treatment trials adequately delivered 
(Carvalho et al. 2012). Their data 
support the hypothesis that lack of 
clinical therapeutic benefit of AD is 
associated with further immunological 
impairment in the presence of a 
concomitant HPA axis disturbance, and 
more importantly biomarkers may be 
able to identify patients who may 
benefit from early access to adjuvant 
therapies. 
Of note, the main inflammatory 
cytokines that appear elevated in 
depressive states are IL-6 and TNF-α, 
which also have been found to be 
increased in treatment-resistant patients, 
compared to patients who would later 
respond to AD (Carvalho et al. 2012; 
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Dunjic-Kostic et al. 2012; O’Brien, 
2007 cfr. Janssen et al. 2010).  
4.1. Undergoing specific effects of 
PICs on depressive-related 
pathways 
According to Miller et al. (2009) 
numerous studies have interest in 
fundamental pathways by which 
cytokines may contribute to depression. 
Cytokine have been shown to access the 
brain and interact with virtually every 
pathophysiologic domain relevant to 
depression, including neurotransmitter 
metabolism, neuroendocrine function 
and neural plasticity.  
4.1.1. Neurotransmitters.  
Once cytokine reach the brain, they 
have the capacity to influence the 
synthesis, release and reuptake of 
mood-relevant neurotransmitters, 
including monoamines (Miller, 2008 
cfr. Miller et al. 2009) such as, 
serotonin, norepinephrine, and 
dopamine. 
Serotonin (5-HT). The 5-HT system is 
undoubtedly one of the most studied 
neurotransmitter systems in depression, 
and SSRIs are the most widely 
prescribed AD medication (Hernandez, 
Mendieta, Pérez-Tapia, Bojalil, Estrada-
Garcia, Estrada-Parra et al. 2009; 
Walker, 2013; Felger and Lotrich, 
2013). Many aspects of the 5-HT 
system are altered in major depression, 
including changes in 5-HT turnover, 
and receptor and transporter binding 
(Felger and Lotrich, 2013). 
The PICs affect 5-HT metabolism by 
reducing tryptophan (TRP) —the 
primary aminoacid precursor of 
serotonin— levels (Miller et al. 2009). 
Cytokines can activate IDO, an enzyme 
which metabolizes TRP, thereby 
reducing serotonin levels (Miller et al. 
2009; Janssen et al. 2010; Roman et al. 
2013). Furthermore, inflammatory 
cytokines, such as IL-1β, may reduce 
extracellular 5-HT levels, via activation 
of the serotonin transporter mechanisms 
(Janssen et al. 2010). Although 
alterations in 5-HT metabolism may not 
be the primary mediator of many 
behavioural symptoms resulting from 
cytokine-induced IDO activity (Dantzer 
et al. 2011; Maes et al. 2010), the 5-HT 
transporter (5-HTT) may serve as a 
biological substrate by which cytokines 
can affect 5-HT neurotransmission and 
subsequently behaviour (Miller et al. 
2009; Felger and Lotrich, 2013). 
Dopamine (DA). Cytokines also have 
been shown to influence the synthesis of 
DA and reduce its availability in 
relevant brain regions (Miller et al. 
2009). Numerous studies mentioned in 
Felger and Lotrich (2013) (such as 
Willner, 1983; Capuron et al. 2001, 
2009; Dunlop and Nemeroff, 2007; 
Majer et al. 2008; Stein, 2008; Felger 
and Miller, 2012), affirm that the 
fatigue of depression, which is often a 
residual symptom of SSRI therapy, is a 
prominent feature of cytokine-induced 
depression, and may represent cytokine 
effects on the basal ganglia and DA 
function. Changes in DA synthesis, 
release and/or receptor signalling have 
been proposed as potential mechanisms 
that may contribute to anhedonic and 
psychomotor symptoms. Miller et al. 
(2009) proposed that cytokine-induced 
effects on the basal ganglia and DA 
may represent an important mechanism 
whereby cytokines inhibit behavioural 
activation.  
Glutamate. The efficacy of N-methyl-
D-aspartate (NMDA) receptor 
antagonist drugs, such as ketamine, in 
rapid AD responses has prompted much 
attention to the role of glutamate in the 
pathophysiology of depression (Dowlati 
et al. 2010; Sanacora et al. 2012 cfr. 
Felger and Lotrich, 2013). This 
neurotransmitter mediates the vast 
majority of excitatory transmission in 
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the brain and is engaged in cognition 
and emotion, processes that are 
commonly affected in depression 
(Roman et al. 2013). According to 
Bansar et al. (2011) and Beumer et al. 
(2012), the signs commonly observed in 
depression, are related to excessive 
levels of glutamate and increased 
glutamatergic neurotransmission (cfr. 
Roman et al. 2013). PICs promote the 
synthesis of the endogenous glutamate 
receptor agonist quinolinic acid, 
increase glutamate release and inhibit 
glutamate re-uptake by astrocytes 
(Felger and Lotrich, 2013), and by 
extension may inhibit the release of 
dopamine (Miller et al. 2009) and 
promote glutamate release through 
activation of extrasynaptic NMDA 
receptors (NMDARs) and contributing 
to glutamate toxicity (Miller et al. 2009; 
Dowlati et al. 2010; Hardingham et al. 
2002, cfr. Felger and Lotrich 2013). 
Moreover, several authors found that 
the activation of NMDA receptors 
perpetuates the pro-inflammatory 
activity of microglia, thus participating 
in the pathology of depression (Dowlati 
et al. 2010; Roman et al. 2013).  
4.1.2. Neuroendocrine system  
HPA axis. In addition to the alterations 
of neurotransmitter systems, numerous 
studies claim that PICs contribute to 
depressive symptoms by activating the 
hypothalamic-pituitary-adrenal axis 
(HPA) and inducing glucocorticoid 
resistance and hypercortisolemia, 
features commonly observed in 
depressive states (Leonard 2001; 
Hernandez et al. 2009; Leonard and 
Myint, 2009; Haroon et al. 2012 cfr. 
Roman et al. 2013). Backing this idea, 
the mentioned study of Carvalho et al. 
2013 supports the hypothesis that the 
presence of HPA axis distribution 
accompanying with further 
immunological impairment may 
produce the lack of clinical therapeutic 
benefit of AD. 
Roman et al. (2013) proposed that 
inflammatory activation of the IS is 
perceived and processed by the brain as 
a stressor and results in corticotropin-
releasing hormone (CRH) release from 
the hypothalamus and subsequent 
activation of the HPA axis and 
adrenocorticotropic hormone (ACTH), 
as well as cortisol, all of which have 
been found to be elevated in patients 
with depression (Miller et al. 2009; 
Janssen et al. 2010; Anders et al. 2013) 
Moreover, according to Mills et al. 
(2013) it is plausible that the 
hyperactivity of the HPA-axis could be 
a consequence of an elevation in 
cytokines, attributable to potentially 
both environmental and genetic 
moderators.  
A pathway by which cytokines seems to 
influence HPA axis is through effects 
on negative feedback regulation. 
Impaired regulation of the HPA axis is 
reflected by decreased responsiveness to 
glucocorticoids (Miller et al. 2009; 
Anders et al. 2013). On the other hand, 
glucocorticoids seems to inhibit the 
production of inflammatory cytokines, 
however, this inhibition also appears 
impaired during both acute depressive 
episodes and in chronic depression 
(O’Brien et al. 2004 cfr. Janssen et al. 
2010; Dowlati et al. 2010). Banasr et al, 
(2011 cfr. Roman et al. 2013) claimed 
that glucocorticoids also involved 
glutamate action, perpetuating 
glutamate toxicity as well as decreasing 
the synthesis of trophic factors.  
Therefore, it is reasonable that HPA-
mediated vulnerability to cytokine-
induced depression represents a more 
general hyper-responsiveness and pre-
existing vulnerability to stress or 
inflammatory challenge (Pace et al. 
2007 cfr. Felger and Lotrich, 2013) 
which may be mediated by alterations in 
glucocorticoid receptor (GR) expression 
or function (Miller et al. 2009)  
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4.1.3. Growth factors. 
Inflammatory cytokines have repeatedly 
been observed to influence both 
neuronal development and apoptosis 
(Roman et al. 2013) by significant 
disturbances in neurogenesis and in the 
release of neurotrophins, including 
brain-derived neurotrophic factor 
(BDNF), underpinning the volumetric 
changes of brain areas such as 
hippocampus and prefrontal cortex in 
depressed individuals (Duman, 1988 
cfr. Walker, 2013). In fact, both stress 
and subsequent inflammatory cytokine 
activity may adversely influence 
neurogenesis and neuroplasticity 
(Roman et al. 2013).  
Miller et al. (2009) claimed that 
cytokines are important for providing 
trophic support to neurons and enhance 
neurogenesis while contributing to 
normal cognitive functions such as 
memory. Nevertheless, in the context of 
prolonged activation, cytokine networks 
can promote an interconnected suite of 
abnormalities including diminished 
neurotrophic support, decreased 
neurogenesis, and increased 
glutamatergic activation, oxidative 
stress, induction of apoptosis and 
dysregulation of neural interactions and 
cognitive function. 
Indeed, there is now a vast body of 
compelling evidence that demonstrates 
BDNF and neurogenesis are 
significantly impaired in depression and 
in animal models of depression 
(Duman, 1998 cfr. Walker, 2013).  
4.1.4. Genetics. 
Twin studies have shown that 
phenotypes depression and increased 
immune activation are heritable, and 
that the link between immune activation 
and depression, at least in part, is due to 
shared genes regulating immune 
function and inflammatory response 
(Bufalino et al. 2012). Interactions 
between immune-cells, monoamine, 
endocrine system, and neuropeptides 
seem to be variously related with 
several functional gene polymorphisms 
associated with vulnerability to 
depression or with certain symptom 
dimensions of this cytokine-induced 
depression as Felger and Lotrich (2013) 
highlighted.  
By these findings has been raised that 
specific polymorphisms may be 
associated with risk for specific sets of 
symptoms (Felger and Lotrich, 2013). 
Therefore, identifying inflammatory 
biomarkers that confer vulnerability to 
or protection from certain aspects of 
cytokine-induced depression and may 
detect patients who are less likely to 
respond to treatment and provide insight 
into the potential mechanisms of 
cytokine effects on behaviour and novel 
treatment strategies (Felger and Lotrich, 
2013; Miller et al. 2009).  
Felger and Lotrich (2013) found 
evidence of functional polymorphisms 
in the promoter region of the IL-6 gene 
—the genotype that produces more IL-
6— was found to be associated with 
depression. It's also been reported that a 
serotonin reuptake promoter 
polymorphism (5-HTTLPR) was 
associated with depression but primarily 
with neurovegetative symptoms and not 
the more psychological symptoms 
(Bufalino et al. 2013; Felger and 
Lotrich, 2013). However, two studies 
found no effect of the 5-HTTLPR 
polymorphism in IFN-α-induced 
depression (Kraus et al. 2007; Sye et al. 
2010 cfr. Bufalino et al. 2013) 
Many other polymorphisms on 
depression-related pathways have been 
found. For example, a polymorphism 
from BDNF (Val/Met allele) was 
associated with the more psychological 
and cognitive symptoms of depression 
(Felger and Lotrich, 2013; Miller et al. 
2009). Also, functional polymorphisms 
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in genes involved in DA 
neurotransmission and GR and CRH 
receptor 1 (Felger and Lotrich, 2013). 
 
4.2. Genetic predisposition to 
treatment response 
Another important variant on the 
genetics studies in this field of study is 
the one focused in the relationship 
between pro- and anti-inflammatory 
cytokines genes and the efficacy of 
pharmacological treatment, as a 
potential use of pharmaco-epigenetic 
biomarker at the baseline predictors of 
AD response (Powell et al. 2013). 
The first genetic study in IL-1Β genes 
(IL1-β-511(C/T)), Yu et al. (2003) (cfr. 
Bufalino et al. 2013) studied the C-
511T polymorphism in a sample of 157 
patients with MDD and 112 controls but 
no significant difference in either 
genotype or allelic distribution was 
found between the two groups. 
However, a subgroup of MDD patients 
who were homozygous for the “low 
producer”, -511C allele, were found to 
have higher depressive symptom 
severity and less favourable response to 
fluoxetine treatment when compared 
with -511T carriers. They also found 
that the C genotype of C-511TSNP, 
which codes for the IL-1β receptors, 
was associated with poorer therapy 
outcome after 4 weeks of AD treatment 
(Yu et al. 2003a, cfr. Bufalino et al. 
2013; Janssen et al. 2010). Janssen et al. 
(2008) also found that a combination of 
genetic variation in the introns of IFN-
γR1/2 receptor and of MAPK6/8 was 
correlated to AD treatment response 
(cfr. Janssen et al. 2010).  
The more exhaustive study of Baune et 
al. (2010), with 256 Caucasian patients 
with MDD(145 women, 111 men) were 
genotyped for variants rs16944, 
rs1143643, and rs1143634 in the IL-1β 
gene (2q14). Response to AD treatment 
over 6 weeks was defined as remission 
and response (>50% decrease on 
Hamilton Rating Scale for Depression–
21-question). Therefore, they suggest a 
negative genetic effect of the IL-1β 
gene involving the GG genotypes of 
two SNPs (rs16944, rs1143643) on 
pharmacological response and 
amygdala and ACC function that taken 
together increase the risk of non-
remission over 6 weeks of AD treatment 
in MDD (Baune et al. 2009). 
The studies in genetics show various 
polymorphisms in genes related to 
cytokine production and action that can 
cause vulnerability to suffer MDD. The 
“low IL-1β producer” polymorphism 
was associated with higher depressive 
symptom severity and less reaction to 
treatment, compared to the “high IL-1β 
producer”.  In essence, all this findings 
reveal that cytokine function may vary 
among individuals depending on each 
individual genotype. Ergo, genetics can 
make you more or less vulnerable to 
suffer this disorder or, by contrast, make 
you more or less responsive to 
pharmacological treatment. 
Up to now, we have seen how the 
different PICs interact with the CNS, 
the endocrine system and how they 
depend on genetics polymorphisms. In 
the next few pages we will, briefly 
explain the interactions between the 
leading treatment for MDD and the IS, 
and how this interaction influence the 
efficacy of these treatments regarding 
the antidepressant-resistant patients.  
5. Antidepressant therapy of Major 
Depressive Disorder  
According to Walker (2013) the 
prescription of SSRIs is a major 
component in the medical treatment of 
mood related psychopathology. We will 
now discuss the influence of AD on 
cytokines function and its efficacy 
within the treatment of MDD, i. e. the 
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impact of AD on cytokines and the 
influence of cytokines in AD function, 
regarding the high rates of non-
responsive patients with MDD to 
pharmacological treatment. 
5.1. Antidepressants effects on 
cytokine function.  
It is now widely accepted that AD have 
effect on cytokine function (Xia, 
DePierre, and Nassberger, 1996; 
Szuster-Ciesielska, Tustanowska-
Stachura, Slotwinska, Marmurowska-
Michalowska, and Kandefer-Szersze, 
2003; Diamond, Kelly and Connor, 
2006; Miller et al. 2009; Janssen et al. 
2010; Maes et al. 2012; Anders et al. 
2013). Recently, several studies have 
analysed the influence of AD on 
cytokine levels and function, in both in 
vitro and ex vivo studies (Janssen et al. 
2010).  
But before we start this part, and in 
order to understand this interaction, we 
must go back to the sickness behaviour, 
a behavioural complex induced by 
infections and immune trauma mediated 
by PICs. It is an adaptive response that 
enhances recovery by conserving 
energy to combat acute inflammation 
(Maes et al. 2012).  
It is postulated that AD may prevent the 
onset of such sickness behaviour by 
modulating PICs. Depressed patients, 
who are otherwise healthy, have 
increased levels of PICs (IL-1, IL-6, 
TNF-α, etc.), acute-phase proteins, 
chemokines, and adhesion molecules 
(Miller et al. 2009; Janssen et al. 2010). 
Pharmacologic interventions that have 
established antimicrobial, immune-
enhancing, or anti-inflammatory 
properties also merit more study for 
their potential AD effects. For example, 
minocycline, a second-generation 
tetracycline antibiotic, has demonstrated 
anti-inflammatory and AD effects in 
both human and animal studies (Pae et 
al. 2008, cfr. Anders et al. 2013). Or, 
Xia et al. (1996) showed that the AD 
imipramine, clomipramine, 
amitriptyline, fluoxetine and citalopram 
all inhibit transformation of 
lymphocytes to blastoid forms. The 
results may indicate that AD affects 
alterations in human immune cells and, 
therefore, they may also affect cytokine 
production by immunocompetent cells. 
It should be noted that neither In vitro 
or Ex vivo methods simulate true 
biological processes and while these 
methods have established themselves as 
standards in immunological research in 
neuropsychiatric disorders, some care 
needs to be taken in extrapolating from 
these studies to the human condition 
(Janssen et al. 2010). 
Xia et al. (1996) studied how tricyclic 
AD (TCAs) influences cytokine release 
by T lymphocytes and monocytes 
respectively. They demonstrate that the 
TCAs imipramine, clomipramine and 
the SSRI citalopram inhibit cytokine 
release from human T cells, as well as 
from monocytes in vitro. For example, 
Citalopram was equality as potent as 
imipramine and clomipramine in 
inhibiting IL-6 release after long-term 
exposure of monocytes to LPS 
(lipopolysaccharide), and all TCAs 
elevated intracellular cAMP 
concentrations significantly in T 
lymphocytes and monocytes. This 
inhibition may be related to the 
mechanism underlying the therapeutic 
efficiency of these drugs in patients 
with major depression, a possibility 
which should be further explored in the 
future.  
Research by Szuster-Ciesielska, et al. 
(2003), found that AD imipramine and 
minserine decreased the production of 
PICs (IL-2, IL-4, INF-γ and IL-12) 
while they stimulated anti-inflammatory 
cytokines such as IL-10 and TGF-β.  
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Following the same stream, and also in 
an in vitro experiment, Diamond et al. 
(2006) examined the effect of first and 
second generation AD, with selectivity 
for the serotonin transporter (fluoxetine 
and clomipramine) or the noradrenaline 
transporter (reboxetine and 
desipramine) on monocyte and T-cell 
derived cytokine production. Their 
sample was made by 3 male and 5 
female; between 22.6 and 2.3 years. 
Overall, the data generated in this study 
indicate that IFN-α producing T-cells 
are the major target of the 
immunomodulatory actions of AD. 
Their findings showed that in vitro 
exposure to AD largely fails to alter 
LPS-induced cytokine production is 
consistent with a study of Kubera 
(2004) where a number of AD failed to 
suppress TNF-α production from 
diluted whole blood, and is also 
consistent with an in vivo study 
Yirmiya et al. (2001) in rats where 
treatment with imipramine and 
fluoxetine failed to alter LPS-induced 
IL-1h or TNF-α expression. However 
their data are at variance with a 
previous study indicating that AD 
suppress production of monocyte-
derived PICs in human peripheral blood 
mononuclear cells (PBMC’s) (Xia et al. 
1996; Diamond, et al. 2006) 
Overall, the in vitro studies consistently 
demonstrate that AD medications 
produce a strong immunosuppressive 
effect on whole blood of both depressed 
patients and healthy volunteers (cfr. Xia 
et al. 2006). 
In order to name some ex vivo study, 
Lanquillon et al. (2000) found that in 
patients with an MDD, the treatment 
response to an AD is related to a 
differential pattern of immune 
activation including production of the 
cytokines IL-6 and TNF-α, IL-6 
production was decreased in patients 
who would later responded to treatment, 
but was elevated for patients who would 
prove to be therapy resistant. Production 
of TNF-α was increased in both groups. 
After treatment with amitryptyline, 
cytokine production normalized for all 
patient groups (Lanquillon, Krieg, 
Bening-Abu-Shach and Vedder, 2000).  
As pointed out in Janssen et al. (2010) 
meta-analysis, in contrast with the 
findings that depression is associated 
with higher inflammatory cytokine 
levels, Rothermundt et al. (2001a) 
found that cytokine levels of IL-2 and 
IFN-α were decreased during the acute 
phase of depression and returned to 
normal levels after treatment. For the 
anti-inflammatory cytokine IL-10, a 
similar pattern was seen, with decreased 
levels during the acute phase and 
normalization after treatment. In a later 
study, Rothermundt et al. (2001b) found 
no difference of IL-1β production 
before and after treatment (Janssen et 
al. 2010), and in the same meta-
analysis, they quote Anisman et al. 
(1999) study who were not able to 
detect differences in IL-1β. 
These reviewed papers have studied the 
existing relation and interaction 
between AD and PICs, showing that for 
example, fluoxetine and citalopram alter 
cytokine production. However, the 
results of these experiments are 
sometimes contradictory as some have 
demonstrated the inhibition of PICs and 
the stimulation of anti-inflammatory 
cytokines, while some other found that 
AD failed on suppressing PICs. 
 
5.2. Antidepressants fail to enhance 
depressive symptoms. 
Alterations in noradrenergic and 
serotonergic function in the central 
nervous system (CNS) have been 
implicated in the pathophysiology of 
depression and the mechanism of action 
of AD drugs (Charney, 1998). Several 
monoamine-based pharmacological 
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drug classes have been developed and 
approved for the treatment of MDD; 
however, remission rates are low (often 
less than 60%) and there is a delayed 
onset before remission of depressive 
symptoms is achieved (Hillhouse and 
Porter, 2015). The results of a series of 
investigations confirm the importance 
of monoamines in the mediation of 
depressed mood, but also suggest that 
other brain neural systems may have 
more of a primary role than previously 
thought in the pathophysiology of 
depression (Charney, 1998). However, 
in its original form it is clearly 
inadequate, as it does not provide a 
complete explanation for the actions of 
AD, and the pathophysiology of 
depression it remains unknown. The 
hypothesis has evolved over the years to 
include, for example, adaptive changes 
in receptors to explain why there should 
be only a gradual clinical response to 
AD treatment when the increase in 
availability of monoamines is rapid 
(Hirschfeld, 2000). 
The SSRIs and tricyclic AD (TCAs) are 
all recognized to alter monoaminergic 
signalling by blockading 5-HT 
reuptake, NE reuptake or both (Hyttel, 
1993; Owens et al. 1997; Shank et al. 
1988). But despite the widespread 
prescription of these medications, their 
use has been a constant subject of 
controversy and sometimes heated 
debate (Walker, 2013). While the 
majority of investigations (cfr. Walker, 
2013) have supported the efficacy of the 
SSRIs, several notable studies have 
suggested that this is not the case, 
arguing that AD possesses little clinical 
utility (Kirsch et al. 2008; Fournier et 
al. 2010 cfr. Walker, 2013). 
Evidence suggests that of those 
receiving adequate medication trials, 
most will not achieve remission 
following initial treatment and nearly 
one-third will not achieve remission 
even following several treatment steps 
(Rethorst, Toups, Greer, Nakonezny, 
Carmody, et al. 2012). Remission of 
symptoms or non-response to treatment 
typically refers to a situation in which 
patients fail to respond to standard 
doses of medication, administered 
continuously for a minimum duration of 
six weeks (Fava, and Davidson, 1996 
cfr. Walker 2013). The non-response 
rate have been estimated to be between 
30 and 50% of patients (Walker, 2013) 
The high rates of non-responsive 
patients to SSRIs has brought 
controversy regarding its efficacy as 
main treatment for depression, leading 
to question whether the monoamine 
theory provides a complete 
neurobiological account of depression 
(Hirschfeld, 2000; Walker, 2013). Of all 
the other compelling non-
monoaminergic and possibly 
complementary hypothesis of 
depression, the inflammatory theory is 
now getting the most attention within 
literature (Walker, 2013). Research of 
Dunjic-Kostik et al. (2013) seems to be 
in favour of the notion that a positive 
correlation between PICs and the 
treatment efficacy represents a possible 
trait marker of atypical depression, 
while IL-6 elevation could be a state 
marker of acute exacerbation, especially 
in melancholic depression. 
We mentioned before some genetics 
vulnerabilities which may provoke 
different types or subtypes of 
depression, bringing to debate whether 
depression should or should not be 
considered as a homogenous condition. 
Genetic vulnerabilities may also play a 
role on the responsiveness to treatment 
in depression, as for example in Yu et 
al. study where a subgroup of MDD 
patients who were homozygous for the 
“low producer”, -511C allele, were 
found to have higher depressive 
symptom severity and less favorable 
response to fluoxetine treatment when 
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compared with -511T carriers (cfr. 
Bufalino et al. 2013).  
Miller et al. 2009 found evidence 
regarding that increased inflammatory 
activity prior to treatment has reported 
less response to AD, lithium, or sleep 
deprivation in depressed patients. 
Moreover, several studies such as 
Dowlati et al. 2010 reports significantly 
higher concentrations of PICs (TNF-α 
and IL-6) in depressed patients with a 
history of non-response to AD 
compared with control subjects. In 
addition, nascents studies suggests that 
functional allelic variants of the genes 
for IL-1 and TNF-α, may increase the 
risk for depression and may be 
associated with reduced responsiveness 
to AD therapy (Millet et al. 2009). Of 
note, AD treatment has been associated 
with decreases in inflammatory markers 
in 11 of 20 studies according to Miller 
et al. 2009 that examined immune 
responses as a function of AD therapy.  
The study of Lanquillon et al. (2000) 
with a final sample of 24 patients 
matched with 15 controls during 6 
weeks. Their results show that IL-6 
levels at admission dichotomized 
patients into subsequent responders and 
nonresponders; whereas, the 
unstimulated secretion of TNF-α was 
uniformly elevated in both patient 
subgroups at admission and declined 
according to the psychopathological 
improvement. After treatment, IL-6 
levels were uniformly normalized, 
regardless of the clinical outcome. They 
could state that, in their sample, the 
production of IL-6 seemed to be a 
predictive marker for the treatment 
response; whereas, the changes in TNF-
α levels paralleled the clinical course. 
The observed inconsistency in research 
results might be well due to the often 
disregard confounding factors such as 
lack of exercise or sleep, smoking 
habits, use of alcohol, comorbid 
disorders, medications (Janssen et al. 
2010; Goldstein et al. 2009, cfr. Dunjic-
Kostic et al. 2013) gender or age among 
many other factors. 
By now we have observed how 
cytokines modulate the onset of this 
disorder through different pathways and 
the effectiveness of the pharmacological 
treatment. Noting that elevated levels of 
PICs affect antidepressants function and 
making individuals non-responsive to 
treatment.  Even though evidence show 
that the monoaminergic hypothesis is 
not enough to explain the onset of this 
disorder, the principal pharmacological 
treatment is based on this hypothesis by 
belief (and some studies showing) that 
monoamine-based drugs act as anti-
inflammatory in depressed patients, 
lowering levels of PICs.  
Although there is evidence showing that 
antidepressants may have anti-
inflammatory properties, 
antidepressants fail to enhance 
depressive symptoms in a large number 
of depressive individuals. The non-
responsiveness of some individuals is 
belief to be consistency of elevated 
levels of specifics PICs. In the next few 
pages we will briefly expose other 
treatment approaches such as anti-
inflammatory drugs or behavioural 
therapies shown to help the 
pharmacological treatment lowering 
PICs or elevating anti-inflammatory 
cytokines. 
6. Other treatment approaches 
Converging evidence suggests that 
depression is often an 
inflammatory/immune-mediated 
response to infection, vulnerability to 
infection, and/or chronic activation of 
the innate IS. This inflammatory 
response is stimulated by increased 
production of PICs, which have wide-
ranging effects on both neuroendocrine 
and neuronal systems, including an 
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inhibitory influence on serotonergic 
transmission (Anders et al. 2013). 
The notion that moods may serve as a 
behavioural defense against infection, 
carry important implications for 
understanding the causes, treatment, and 
prevention of depression. Some of these 
implications pose a challenge to 
conventional wisdom; for example, if 
symptoms of depression are serving a 
protective function in the face of 
immune challenge, then the goal of 
reducing depressive symptoms to ease 
emotional distress should be balanced 
against the need to first identify and 
treat possible underlying immune 
factors (Anders et al. 2013). 
Inflammation, as many authors affirm 
(cfr. Janssen et al. 2010)  is closely 
linked with behavioural parameters such 
as lack of exercise or sleep, alcohol 
abuse, and smoking, as well as with 
medical comorbidities including 
coronary artery disease, obesity and 
insulin resistance, osteoporosis, and 
pain (Janssen et al. 2010; Rethorst et al. 
2013). Some of these factors 
influencing immune vulnerability are 
commonly addressed in mental health 
treatment settings and can be alleviated 
with traditional forms of therapy 
including cognitive behaviour therapy 
and mind-body relaxation techniques, as 
well as pharmacological interventions 
(Anders et al. 2013). 
6.1. Anti-inflammatory 
pharmacological treatment 
A promising line of research in the 
search for improved pharmacologic 
treatments of depression involves anti-
inflammatory cytokine antagonists. For 
example, in animal studies, the use of 
the IL-1β receptor antagonist IL-1ra 
prevented the development of 
depression-like behavioural and 
neurochemical changes in response to 
chronic stress exposure (cfr. Anders et 
al. 2013). 
In a different line of investigation, 
Warner-Schmidt et al. (2011) assessed 
whether nonsteroidal anti-inflammatory 
drugs (NSAIDs) could play a role in the 
treatment outcome of depressed 
individuals taking SSRIs. They 
postulated evidence that AD increase 
brain levels of certain cytokines, which 
increase p11 levels (a small acidic 
protein that interacts with specific 
serotonin receptors to regulate their 
trafficking and influence their 
localization at the cell surface), which 
then induce antidepressant-like 
behavioural responses (Warner-
Schmidt, Vanover, Chen, Marshall and 
Greengard 2011), and found that human 
patients reporting concomitant NSAID 
or other analgesic treatments showed a 
reduced therapeutic response to 
citalopram. Finally they suggest that 
NSAIDs and other analgesics may 
potentially interfere with the therapeutic 
efficacy of SSRIs. 
And, at the end of their paper 
“Antidepressant effects of SSRIs are 
attenuated by anti-inflammatory drugs 
in mice and humans”, they adventure to 
urge the medical community to consider 
these findings when designing treatment 
strategies for their patients that include 
SSRIs (Warner-Schmidt et al. 2011). 
In studies of adults with depression, 
cytokine antagonists have also been 
found to have antidepressant-like 
effects. However, conflicting results 
have been reported for TNF-α 
antagonists such as infliximab, in that 
depressed patients with higher levels 
inflammatory markers especially C-
reactive protein (CRP) prior to 
treatment may benefit from such 
treatment as opposed to a general 
benefit in depression (Raison et al. 2012 
cfr. Mills et al. 2013). Moreover, anti-
inflammatory medications have also 
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been found to have antidepressant-like 
effects. For example, acetylsalicylic 
acid added to fluoxetine led to increased 
remission rates in depressed patients 
previously unresponsive to fluoxetine 
alone (Mendlewicz et al. 2006 cfr. Mills 
et al. 2013).  
Other agents and treatment programs 
that have anti-inflammatory actions or 
block actions of cytokines, such as 
physical exercise and omega-3 
polyunsaturated fatty acids (PUFAs), 
may have a role in the treatment of 
depression (Mills et al. 2013).  
 
6.2. Behavioural treatment 
Physical exercise is believed to exert 
similar anti-inflammatory effects 
improving depressive symptoms, but it 
is unknown if exercise affects directly 
inflammation in MDD patients 
(Rethorst, et al. 2012), some other 
authors claim that the effect of exercise 
is more globally mediated through 
various pathways of the neuroIS (Eyre 
and Baune, 2011 cfr. Mills et al. 2013). 
As recently extensively reviewed by 
these authors, consistent 
exercise/physical activity has been 
shown to reduce levels of IL-1β, TNF-α 
and IL-6, and Kaliman’s group research 
on epigenetic changes related the  
response to environmental exposures 
such as diet and physical exercise with 
reduced levels of cytokines detected in 
human peripheral tissues   (cfr. 
Kaliman, Álvarez-López, Cosín-Tomás, 
Rosenkranz, Lutz, et al. 2014).  
On the other hand, a meta-analysis of 10 
double-blind, placebo-controlled studies 
in adult patients with mood disorders 
receiving omega-3 polyunsaturated fatty 
acids, indicated an AD effect of omega-
3 PUFAs (Lin and Su, 2007 cfr. Mills et 
al. 2013). However, the authors noted 
that it is premature to draw firm 
conclusions based on the findings due to 
the heterogeneity of the different study 
methodologies. Given the implication of 
omega-3 PUFAs in depression, it is 
therefore interesting that omega-3 
PUFAs have the capacity to decrease 
the production of PICs, and exert strong 
anti-inflammatory effects (Maes et al. 
2009 cfr. Mills et al. 2013). 
Meditation practices may impact 
physiological pathways that are 
modulated by stress and relevant to 
disease (Pace, Negi, Adamec, Cole, 
Sivilli, et al. 2008; Kaliman et al. 
2014). Mindfulness based interventions, 
which intentionally cultivate attentional 
skills, have become an increasingly 
popular approach and have been 
associated with improvements in 
physical health; however, the 
mechanisms underlying these changes 
are unclear. However, it may be that the 
effect of compassion meditation on 
stress responses is dose dependent and 
only apparent in individuals who 
commit to some minimum amount of 
practice time (Pace et al. 2008). 
Tomfohr et al. (2013) explored the 
relationship between trait mindfulness, 
blood pressure (BP) and IL-6 (Tomfohr, 
Pung, Mills, Paul, and Edwards 2013). 
Their study had 130, young adults [M 
(SD) age = 21.7(2.7) years] reported 
trait levels of mindfulness (Five Facet 
Mindfulness Questionnaire). 
Mindfulness meditations involve the 
development of awareness of present-
moment experience with a 
compassionate, non-judgmental stance 
(Hölzel et al. 2011). Several studies 
have documented the positive impact of 
mindfulness-based programs on 
symptoms of anxiety and depression, as 
well as improvements in sleep patterns 
and attention (cfr. Hölzel et al. 2011). 
On the epigenetic study of Kaliman et 
al. (2014), they demonstrated that 
mindfulness-based stress reduction 
(MBSR) program reduced cytokine 
secretion, oxidative stress and DNA 
damage, increased natural killer cell 
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activity and decreased interleukin 
secretion in women recently diagnosed 
with early stage breast cancer, and 
increased CD4+ T lymphocyte counts in 
HIV infected subjects. 
Given the long-recognized ability of 
cortisol to suppress innate immune 
activity, it is intriguing that participants 
who practiced compassion meditation 
had reduced IL-6 responses in the 
absence of clear changes in cortisol 
reactivity to the Trier social stress test 
(TSST). Pace et al. (2008, 2006) has 
reliably measured increases in this 
cytokine in response to the TSST in 
separate populations and has shown that 
medically healthy men with depression 
have increased IL-6 responses to the 
TSST when compared to men without 
depression. 
7. Discussion  
Since the introduction of the 
macrophage hypothesis of depression in 
the earliest 1990 by Smith, it has 
become clear that there is a bidirectional 
relationship between depression and 
immune functioning (Janssen et al. 
2010). 
Present pharmacological treatment of 
depression fails in a higher percentage 
than, pharmacological industries, health 
careers or depressed patients would like. 
Lots of hypothesis has been made, and 
the one that concerns this paper has 
been receiving special attention in the 
last years. The cytokine hypothesis of 
depression is one of the results of this 
general effort of health sciences to 
lower the percentage of non-remission 
patients and is leading the investigation 
to the awareness of two concrete 
interleukins, IL-6 and TNF-α in MDD, 
especially atypical cases, those who 
does not respond correctly to any 
treatment. 
In this paper we have briefly reviewed 
four alternative or complementary 
treatments to AD, one half is 
pharmacological, and the other is 
behavioural proposals of treatment: 
omega3, nonsteroidal anti-inflammatory 
drugs, exercise and mindfulness. 
Mindfulness-based technique has 
demonstrated to have significant similar 
effects than anxiolytics in imaging 
magnetic resonance therefore meaning 
that it decreases stress and enhances 
quality of life. It is currently 
demonstrated that helps to reduce PICs 
in MDD patients, so it may be 
interesting to consider the possibility of 
mixing both AD therapy with learning 
and application of mindfulness. 
Another important approach to enhance 
MDD treatment is pharmacogenomics, 
which focuses primarily on genetics. In 
this paper we have exposed that 
depending on the polymorphisms or 
methylation of some genes, the efficacy 
of the AD may vary. There is an 
increasing need of further investigation 
in this field, with the intention of 
determining either different biomarkers 
for AD response, alleles and 
polymorphisms that affect the 
predisposition to suffer MDD, the 
response to AD or PICs levels prior 
treatment. 
Last, we find relevant to mention that 
there are still some hypothesis about 
cytokines depression-induced, such as 
the unbalance of pro and anti-
inflammatory cytokines in depressed 
patients, and the relation between the 
subtype of depression and cytokine 
levels. As noted, in various 
investigations, it has been found a 
relation between MDD with 
melancholic features to be more related 
with higher levels of IL-6, while MDD 
with atypical features was related with 
decreased levels of IL-6 and TNF-α 
(Fumaz, Gonzalez-Garcia, Borras, 
Ferrer, Munoz-Moreno et al. 2009; 
Dunjnc-Kostic, et al. 2012). We believe 
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these hypotheses should also been taken 
to consideration inasmuch as they may 
predict the disorder onset, and treatment 
inequality in MDD patients.  
Although there is now a strong 
agreement/consensus about the 
existence of the interaction between the 
immunological system and the CNS, 
and therefore with AD, there are still 
open debates about the real importance 
of this relationship. Many fronts remain 
still to investigate and discuss about, but 
given the relevance of the Major 
Depressive Disorder in the more 
developed countries, laboratories, 
hospitals and universities from all over 
the world are investigating in the 
possibilities to either enhance the 
efficiency of the current AD or to find 
another way to heal depressed patients 
8. Limitations 
Our paper main limitation is the 
heterogeneity of the samples, 
contradictory results or other 
uncontrolled factors that may influence 
on PICs or MDD, such as the diagnostic 
criteria used for the assessment of 
depression, across the various studies 
reviewed. Also, due to the relative 
youth of this subject, most of these 
findings are not replied.  
Therefore we propose further 
investigation on this hypothesis and all 
its variants together with the alternative 
therapies which may contribute to the 
enhancement of the treatment efficacy.  
9. Conclusions 
- The role for dysregulation of the IS 
in the pathogenesis of MDD is well 
established. Biological mechanisms 
involved in the relationship between 
immune activation and depression 
could be influenced by underlying 
genetic vulnerability. 
- The first clue about the relation 
between the IS and the CNS was 
sickness behaviour which symptoms 
resemble to depression. 
- Until recently the main hypothesis of 
depression was based on 
monoamine-neurotransmitters 
disturbances. However, the lack of 
efficacy of monoamine-based 
treatments has put into consideration 
whether the monoamine theory 
provides a complete neurobiological 
account of depression. 
- There are numerous studies 
addressing fundamental pathways by 
which cytokines may contribute to 
depression such as monoamine 
pathways (5-HT, DA or Glu), 
neuroendocrine system (HPA axis), 
growth factors (BDNF) and genetics. 
- Increased levels of PICs have been 
found repeatedly in depressed 
individuals, prompting the 
formulation of the “cytokine 
hypothesis of depression”.  However, 
several studies did not found any 
association between cytokines levels 
and symptoms of depression. 
- Studies have analysed these 
influences finding that AD affects 
human immune cells then they also 
may affect cytokine production. 
Tricyclic and SSRIs, both 
demonstrate inhibition of cytokine 
release and production of other PICs. 
Ex vivo studies observed that 
treatment response to AD was related 
to the pattern of immune activation. 
- Other factors non-widely taken into 
consideration in treatment response 
are lack of exercise, smoking, 
medications or even gender and age, 
may play an important role on 
treatment-response rates. 
- Lots of nascent pathways have been 
hypothesized in order to ameliorate 
the symptoms and help AD 
accomplish its purpose. An anti-
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inflammatory cytokine antagonist 
has been taken into consideration; 
however conflicting results have 
been reposted. 
- Other agents considered to have anti-
inflammatory actions are exercise 
and Omega-3 fatty acids, but it 
remains unknown the mechanism by 
which these may act in order to 
decrease pro-inflammatory cytokines 
levels. 
- Meditation practices also seem to 
impact physiological pathways that 
are modulated by stress and relevant 
to MDD, such as mindfulness-based 
interventions. 
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FE D’ERRADES 
Després de l’entrega del treball de fi de grau, i en posteriors revisions, les autores del 
treball “Treatment failure in major depression associated with chronic inflammation of 
the immune system: a psychoneuroimmunological hypothesis” declaren que han trobat 
errors en els seguents apartats: 
A totes les pàgines: el número a peu de pàgina està en una font diferent. 
Pàgina 1, es localitza l’estudia Barcelona i és realitzat a Bellaterra. 
Pàgina 14, paràgraf que comença amb “The SSRIs, tricyclic AD (TCAs) and SNRIs are 
all recognized to alter monoaminergic signalling by blockading 5-HT reuptake, NE 
reuptake or both […]” hauria de ser “The SSRIs and tricyclic AD (TCAs) are all 
recognized to alter monoaminergic signalling by blockading 5-HT reuptake, NE 
reuptake or both”. 
Pàgina 14, paràgrag que comença amb “The high rates of non-responsive patients to 
SSRIs has brought controversy regarding its efficacy as main treatment for depression 
[…]” hi falta una paraula al final, i hauria de quedar: “The high rates of non-responsive 
patients to SSRIs has brought controversy regarding its efficacy as main treatment for 
depression, leading to question whether the monoamine theory provides a complete 
neurobiological account of depression (Hirschfeld, 2000; Walker, 2013). Of all the 
other compelling non-monoaminergic and possibly complementary hypothesis of 
depression, the inflammatory theory is now getting the most attention within literature 
(Walker, 2013). Research of Dunjic-Kostik et al. (2013) seems to be in favour of the 
notion that a positive correlation between PICs and the treatment efficacy represents a 
possible trait marker of atypical depression, while IL-6 elevation could be a state 
marker of acute exacerbation, especially in melancholic depression”. 
Pàgina 18, paràgraf que comença amb “Mindfulness is a relaxation techinique which 
has demonstrated to have significant similar effects than anxiolytics in imaging 
magnetic resonance therefore meaning that it decreases stress and enhances quality of 
life […]” i haría de ser “Mindfulness-based technique has demonstrated to have 
significant similar effects than anxiolytics in imaging magnetic resonance therefore 
meaning that it decreases stress and enhances quality of life”. 
Ens disculpem per les possibles molèsties que aquests errors hagin pogut ocasionar al 
lector. 
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Key stakeholders 
The stakeholders for our paper may be the medical community more concretely; 
healthcare professionals prescribing antidepressant medication and healthcare 
professionals investigating on alternative therapies to decrease the treatment failure 
should be main recipients of the present document, alongside with researchers on the 
antidepressant medication field, patients suffering treatment-resistant depression and its 
families. 
In the last decades, the antidepressant treatment has been a contentious field of research 
in which the leading monoamine based treatment of depression has been letting the 30% 
to 50% of patients with acute phase of major depression without improvement. 
Therefore researchers are constantly searching for the remedy to this blemish in the 
treatment of depression promoting the conception of the cytokine hypothesis of 
depression which defends the idea that cytokines interact not only with the central 
nervous system (CNS), but also with the antidepressant treatment. To the best of our 
knowledge, there is not any study evaluating the efficacy of a dual therapy that may 
include both, the current antidepressants (AD) therapy and one that helps to reduce the 
chronic inflammation of the CNS. This is the reason why we encourage research 
stakeholders to investigate the effectiveness and also the possible differences between 
pharmacological and behavioural treatments efficacy for the chronic inflammation of 
the immune system (IS). 
Thus healthcare professional stakeholders should consider, previous to the selected drug 
therapy, a blood analysis in order to assess whether the patient has a chronic 
inflammation of the CNS, and if so, apply dual therapy including both, the current AD 
therapy and one that helps to reduce the chronic inflammation of the CNS. But since an 
analysis of pro-inflammatory cytokines is very expensive, it would be equally effective 
a generic and simple indicator of inflammation which results to be an inexpensive high-
sensitivity C-reactive protein (hsCRP) which costs less than 5 €. 
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INTRODUCTION 
Psychoneuroimmunology investigates roughly the interaction between the IS and the 
CNS. A relevant body of research has been focusing on both the causes and the 
remedies of major depressive disorder (MDD) which is predicted to be the second 
leading cause of disability by 2020.  
Depressive syndromes and MDD are exceedingly common, they are a chronic and 
recurrent disorder with residual disability, and yet the contributing factors to its nature 
are not entirely understood. The acknowledgment of sickness behaviour was a seed to 
the cytokine hypothesis of depression, which defends that increased levels of pro-
inflammatory cytokines (PICs) are present in MDD patients. It is now generally 
accepted that immune dysregulation plays an important role in the pathogenesis of 
MDD. There are good evidences suggesting that inflammation can contribute to the 
development of depression but it is less evident that blocking inflammation will lead to 
a reduction of depressive symptoms or be efficacious in treatment-resistant depression. 
We aim to clarify how some specific molecules of the immune system (cytokines) 
interact with AD, and how this interaction affects the efficacy of the pharmacological 
treatment in MDD. We also attempt to analyse an alternative depression treatment 
which is based on the hypothesis that improving the inflammatory state of the immune 
system alleviates the depression symptoms.   
METHODOLOGY 
This review encompasses the literature mainly published between 2004 and 2015. The 
limited review to these years obeys the intention to best characterize current thinking 
about the relationship between immune activation and depression. We built a systematic 
review of the pubmed and psychinfo among other databases. We have also searched in 
the firsts reviewed articles’ bibliography in order to select those we found more 
interesting. With an exception for those articles that are the base of knowledge in 
psychoneuroimmunology and those related with depression. The searches applied in the 
databases were Psychoneuroimmunology AND depression AND treatment failure, and 
also, Psychoneuroimmunology AND depression AND cytokines AND antidepressants. 
We have finally used 42 reviews or meta-analysis, all of them in English. 
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RESULTS 
Aetiology hypotheses of Major Depressive Disorder 
The leading hypothesis of depression defends that depression is caused by a deficiency 
in synaptic concentrations of monoaminergic neurotransmitters including serotonin and 
norepinephrine which has been called the monoamine hypothesis of depression and 
has become the basis for most of the treatments in the market. However, the efficacy of 
antidepressant drugs based on the fundamental premise of the monoamine hypothesis 
has been limited, with estimates between 30% and 50% of individuals treated with 
antidepressant medication do not show adequate response. The credibility of the 
monoamine theory and the therapeutic efficacy of these compounds in the treatment of 
depression have been extensively criticized. Research on the immune system and its 
role in the etiology of depression has emerged as an especially promising area for study, 
in particular, the role of immune-activated inflammatory cytokines, a key area of focus 
in understanding the neurobiological pathways that trigger depressive states by way of 
direct and indirect effects on hypothalamic-pituitary-adrenal (HPA) axis, and by altering 
monoamine neurotransmitters in multiple regions of the brain. 
The insufficiency of the monoamine hypothesis to explain several aspects of mood 
regulation has resulted in an extended research for new neurobiological basis of 
depression. Increased levels of PICs have been repeatedly observed in depressed 
individuals prompting the formulation of the “Cytokine hypothesis of depression”. 
Cytokines are the key mediator of 
inflammation; therefore they can alter 
neurochemical and neuroendocrine processes 
that have wide-ranging effects on physiology 
and behaviour. In this review, we focus 
primarily on PICs interleukine-1 (IL-1), IL-6, and Tumour Necrosis Factor-α (TNF-α), 
which together coordinate a variety of cell functions that stimulate and enhance 
inflammation. The most obvious possibility is that cytokines travel to the brain in the 
bloodstream and cross the blood-brain barrier. There are specific receptors for IL-1, IL-
6 and TNF in the brain and neurons. Also blocking IL-1 receptors in the brain can 
prevent some of the sickness like responses to peripheral administration of cytokines. 
Cytokines are secreted proteins by 
immune cells and act on other cells to 
coordinate appropriate immune 
responses. Cytokines include a diverse 
assortment of interleukins, interferons, 
and growth factors. 
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However, as cytokines are large lyophobic molecules they are not likely to cross the 
blood-brain barrier and enter the brain. Numerous investigations proposed different 
mechanisms such as, active transport, weak brain-barrier areas, and the existence of 
receptors inside the blood vessels that may allow cytokines access to the brain; however 
it does not seem to be sufficient to produce psychological changes. There are other 
alternative communication pathways between the brain and the immune system. The 
CNS receives neural and humoral signals about the peripheral inflammatory response 
thought PIC-induced activation of afferent vagal signals at the sensory nuclei of the 
solitary tract. 
The specific effects of PICs on depressive-related pathways are virtually every 
pathophysiologic domain relevant to depression, including neurotransmitters 
metabolism, endocrine system activation and growth factors modulation: 
 
 
 
Chronical elevated of PICs 
Neurotransmitters 
Activation of extrasinaptic 
NMDA 
Increases Glutamate release 
Decreases of tryptophan Decreases 5-HT 
Decreases DA availability 
Growth factor BDNF 
Stress and subsequent inflammatory 
cytokine activity may adversely 
influence neurogenesis and 
neuroplasticity 
HPA axis activation Induces glucocorticoid resistance and hypercortisolemia  
NMDA (N-methyl-D-aspartate receptor); BDNF (Brain-Derived Neurotrophic Factor);  HPA axis (Hypothalamic-Pituitary-
Adrenal axis) 
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Regarding genetics, twin studies have shown that phenotypes depression and increased 
immune activation are heritable, and that the link between immune activation and 
depression, at least in part, is due to shared genes regulating immune function and 
inflammatory response. Interactions between immune-cells, monoamine, endocrine 
system, and neuropeptides seem to be variously related with several functional gene 
polymorphisms associated with vulnerability to depression or with certain symptom 
dimensions of this cytokine-induced depression. This is why we also may encourage a 
genetic research on this psychoneuroimmunologycal field.  
Treatment resistance in major depression disorder  
The selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) 
are recognized to alter monoaminergic signalling by blockading 5-HT reuptake, NE 
reuptake or both; however several notable studies have reported a lack of efficacy, 
arguing that antidepressants possess little clinical utility.  
A positive correlation between PICs and the 
treatment efficacy represents a possible trait 
marker of atypical depression, while IL-6 
elevation could be a state marker of acute 
exacerbation, especially in melancholic 
patients. The prior to treatment increase of inflammatory activity has reported less 
response to antidepressants, lithium, or sleep deprivation in depressed patients. 
Moreover, several studies report significantly higher concentrations of PICs (IL-6 and 
TNF-α) in depressed patients with a history of non-response to antidepressants 
compared with control subjects. 
 Alternative proposals:  
Converging evidence suggests that depression is often an inflammatory/immune-
mediated response to infection, vulnerability to infection, and/or chronic activation of 
the innate immune system. In our extensive research we found a complementary drug 
therapy and three complementary behavioural therapies. 
The complementary drug therapy comes from a promising line of research in the 
search for improved pharmacologic treatments of depression involving anti-
inflammatory cytokine antagonists. For example, the use of the IL-1β receptor 
Remission of symptoms or non-response 
to treatment typically refers to a 
situation in which patients fail to 
respond to standard doses of 
medication, administered continuously 
for a minimum duration of six weeks 
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antagonist IL-1ra, in animals, prevented the development of depression-like behavioural 
and neurochemical changes in response to chronic stress exposure. 
The complementary behavioural therapies are three: 1) physical exercise is believed 
to exert similar anti-inflammatory effects improving depressive symptoms, but it is 
unknown if exercise affects directly inflammation in MDD patients. 2) Relaxation 
techniques, such as Jaboson’s. 3) Meditation which may impact physiological pathways 
those which are modulated by stress and relevant to disease. Although several studies 
have documented the positive impact of mindfulness-based programs on symptoms of 
anxiety and depression, as well as improvements in sleep patterns and attention, we urge 
health community to investigate the mechanisms underlying these changes which 
remains unclear. 
IMPLICATION FOR RESEARCHERS 
Further investigation should be carried in two main streams; the first may seek to 
understand all the causes of the failure in AD treatment; and the second and most 
important should be the investigation in the efficacy of the proposed dual therapy that 
may include both, the current AD therapy and one that helps to reduce the chronic 
inflammation of the CNS. We urge research stakeholders to execute further and deeper 
investigation on this field, to evaluate the effectiveness of the dual treatment. Lines of 
investigation may be whether the AD are necessary or not with the application of these 
techniques and also to determine the % of depressed people whom may benefice of 
these innovation in treatment. 
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Pharmacological treatment is, at present, the first option for battling depressive 
symptoms despite the documented lack of efficacy of antidepressants therapy based in 
the hypothesis that depression might be caused by a dysregulation of monoamine 
levels, such as serotonin or norepinephrine, in the brain. The present review submitted 
by Paula Báez and Laura Andrés from the Universitat Autònoma de Barcelona aims to 
clarify reasons why antidepressants treatment fails in 30 to 50% of depressed patients, 
above all, those suffering Major Depressive Disorder which is expected to be the 
second cause of disability by 2020. Several investigations gathered by the authors show 
a significant interest in agents from the immune system known as cytokines, especially 
pro-inflammatory cytokines. These molecules seem to be implicated in both onset and 
treatment response in depressed individuals.  
 
Pro-inflammatory cytokines are responsible 
for the inflammatory response facing infection 
and causing behavioural changes known as 
sickness behaviour, which are similar to 
depressive symptoms, such as diminished 
sleep and activity, among others. Now that the 
role of pro-inflammatory cytokines in 
depression are not doubted, it has been 
extensively demonstrated that a high 
percentage of unresponsive depressive 
patients have elevated levels of these 
molecules impacting on the efficacy of 
antidepressants. Anyway the authors 
encourage further investigation on this subject.  
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Since the lack of efficacy of monoamine-based pharmacological treatment (in some of 
the individual suffering depression) and the role of pro-inflammatory cytokines are 
demonstrated facts, some investigators bring forward new treatment proposals. All of 
them founded by the belief that alleviating chronic inflammation of the immune 
system and reducing pro-inflammatory cytokines levels will somehow enhance 
depressed symptoms. The alternative therapies proposed by the researchers are “dual 
therapies” in which classic pharmacological treatment is combined with techniques 
demonstrated to reduce pro-inflammatory cytokine levels, such as anti-inflammatory 
cytokines antagonists and meditation. 
 
The authors of this review focus, especially, on 
Mindfulness-based programs which have been highly 
demonstrated to reduce symptoms of anxiety and 
depression, and have been also associated with 
improvements in physical health although the 
pathways underlying these changes are unclear. Mindfulness-based stress reduction 
(MBSR) programs evidence reduction of cytokine secretion, oxidative stress and DNA 
damage, increased natural killer cell activity and decreased interleukin secretion, among 
other benefits in depressed patients. 
 
Even though the results of this investigation are inconclusive the authors propound 
further investigation on this subject, in order to clarify the role of cytokines in treatment 
response and dig deeper into new therapy proposals to bring the spotlight to treatment-
resistant depressive patients.  
 
